132 related articles for article (PubMed ID: 31124963)
1. Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials.
Hu Q; Wang X; Chen Y; Li X; Cao P; Cao D
Medicine (Baltimore); 2019 May; 98(21):e15761. PubMed ID: 31124963
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol.
Lv W; Wang Q; Hu Q; Wang X; Cao D
BMJ Open; 2022 Jul; 12(7):e050558. PubMed ID: 35831044
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer.
Ge L; Hou L; Yang Q; Wu Y; Shi X; Li J; Yang K
Medicine (Baltimore); 2019 Feb; 98(7):e14478. PubMed ID: 30762769
[TBL] [Abstract][Full Text] [Related]
5. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Flaum N; Hubner RA; Valle JW; Amir E; McNamara MG
J Surg Oncol; 2019 Jun; 119(7):932-940. PubMed ID: 30838647
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.
Hashimoto D; Satoi S; Ishikawa H; Kodera Y; Kamei K; Hirano S; Fujii T; Uemura K; Tsuchida A; Yamada S; Yamamoto T; Hirota K; Sekimoto M
Trials; 2022 Feb; 23(1):135. PubMed ID: 35151367
[TBL] [Abstract][Full Text] [Related]
8. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis.
Boeck S; Ankerst DP; Heinemann V
Oncology; 2007; 72(5-6):314-21. PubMed ID: 18187951
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline.
Biagi JJ; Cosby R; Bahl M; Elfiki T; Goodwin R; Hallet J; Hirmiz K; Mahmud A
Curr Oncol; 2023 Jul; 30(7):6575-6586. PubMed ID: 37504342
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a protocol for a systematic review and network meta-analysis.
He S; Zou Y; Li J; Liu J; Zhao L; Yang H; Su Z; Ye H
BMJ Open; 2020 Feb; 10(2):e033917. PubMed ID: 32047017
[TBL] [Abstract][Full Text] [Related]
11. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy.
Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
J Gastroenterol; 2021 Jan; 56(1):101-113. PubMed ID: 33094352
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295).
Raufi AG; Breakstone R; Leonard K; Charpentier K; Beard R; Renaud J; Cavanaugh L; Sturtevant A; MacKinnon K; Almhanna K; Olszewski A; Safran HP
Am J Clin Oncol; 2020 Dec; 43(12):857-860. PubMed ID: 32976178
[TBL] [Abstract][Full Text] [Related]
13. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
14. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
15. History of preoperative therapy for pancreatic cancer and the MD Anderson experience.
Gaskill CE; Maxwell J; Ikoma N; Kim MP; Tzeng CW; Lee JE; Katz MHG
J Surg Oncol; 2021 May; 123(6):1414-1422. PubMed ID: 33831256
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy in elderly patients with pancreatic cancer.
Nagrial AM; Chang DK; Nguyen NQ; Johns AL; Chantrill LA; Humphris JL; Chin VT; Samra JS; Gill AJ; Pajic M; ; Pinese M; Colvin EK; Scarlett CJ; Chou A; Kench JG; Sutherland RL; Horvath LG; Biankin AV
Br J Cancer; 2014 Jan; 110(2):313-9. PubMed ID: 24263063
[TBL] [Abstract][Full Text] [Related]
17. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
18. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H
Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152
[TBL] [Abstract][Full Text] [Related]
19. Completion of adjuvant therapy in patients with resected pancreatic cancer.
DePeralta DK; Ogami T; Zhou JM; Schell MJ; Powers BD; Hodul PJ; Malafa MP; Fleming JB
HPB (Oxford); 2020 Feb; 22(2):241-248. PubMed ID: 31563326
[TBL] [Abstract][Full Text] [Related]
20. A commentary on 'Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study'.
Zhong F; Xieb C; Peng X; Luo J; Yang H
Int J Surg; 2024 Mar; 110(3):1331-1332. PubMed ID: 38051933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
